Adapalene Market
Description
Adapalene Market Size, Share & Trends Analysis Report By Formulation (Gels, Creams, Lotions), By Drug Composition (Adapalene Monotherapy), By Prescription, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
Adapalene Market Summary
The global adapalene market size was estimated at USD 605.5 million in 2025 and is projected to reach USD 789.5 million by 2033, growing at a CAGR of 3.9% from 2026 to 2033. The market is experiencing steady growth due to the increasing prevalence of acne and other dermatological disorders, growing awareness of dermatology treatments, and expanding access to topical retinoid therapies.
Adapalene, a third-generation topical retinoid widely used to treat acne vulgaris, works by regulating skin cell turnover, reducing inflammation, and preventing clogged pores. Because of its strong efficacy and relatively favorable safety profile compared with earlier retinoids, adapalene has become one of the most commonly prescribed topical agents for mild-to-moderate acne and is increasingly incorporated into combination therapies with benzoyl peroxide or antibiotics.
One of the major factors driving demand for adapalene globally is the high and rising prevalence of acne vulgaris. For instance, in May 2025, a study published by MDPI AG on the epidemiology of acne in the current era: trends and clinical implications highlighted that acne remains a highly prevalent inflammatory skin condition worldwide. This condition affects approximately 9.4% of the global population, with increasing incidence observed among both adolescents and adults, particularly women. These epidemiological trends emphasize the growing need for effective acne therapies such as topical retinoids, including adapalene, in dermatological treatment. As a result, acne consistently ranks among the most prevalent skin diseases globally, creating sustained demand for effective pharmacological treatments such as topical retinoids, including adapalene.
In addition to adolescents, adult acne is becoming increasingly common, particularly among women. Dermatological studies indicate that acne is no longer confined to teenage years, with a growing number of individuals experiencing persistent or late-onset acne beyond the age of 25. As per the article published by MDalgorithms Inc. in August 2025, it suggests that around one-fifth of adults aged 25-39 still experience acne, indicating a broader patient population requiring long-term dermatological treatment. This shift toward adult acne prevalence has significantly expanded the addressable market for topical therapies like adapalene, which is frequently used as a maintenance treatment due to its ability to prevent new lesions and control chronic inflammation.
The market is also benefiting from ongoing pharmaceutical innovation and new combination therapies incorporating adapalene. Such product developments are expanding therapeutic options and strengthening the clinical adoption of adapalene as part of multidrug acne management strategies. Furthermore, lifestyle and environmental factors are contributing to the increasing burden of acne worldwide. Rising urban pollution, dietary changes, hormonal imbalances, and stress levels have been associated with worsening acne incidence in many regions. At the same time, the growing influence of social media and increased awareness about skin health and aesthetics have encouraged more individuals to seek dermatological treatment for acne and related conditions. As acne can lead to scarring, pigmentation, and psychological distress, demand for effective treatments such as adapalene continues to rise across both prescription dermatology and over-the-counter skincare segments.
Global Adapalene Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global adapalene market report based on formulation, drug composition, prescription, indication, distribution channel, and region:
Adapalene Market Summary
The global adapalene market size was estimated at USD 605.5 million in 2025 and is projected to reach USD 789.5 million by 2033, growing at a CAGR of 3.9% from 2026 to 2033. The market is experiencing steady growth due to the increasing prevalence of acne and other dermatological disorders, growing awareness of dermatology treatments, and expanding access to topical retinoid therapies.
Adapalene, a third-generation topical retinoid widely used to treat acne vulgaris, works by regulating skin cell turnover, reducing inflammation, and preventing clogged pores. Because of its strong efficacy and relatively favorable safety profile compared with earlier retinoids, adapalene has become one of the most commonly prescribed topical agents for mild-to-moderate acne and is increasingly incorporated into combination therapies with benzoyl peroxide or antibiotics.
One of the major factors driving demand for adapalene globally is the high and rising prevalence of acne vulgaris. For instance, in May 2025, a study published by MDPI AG on the epidemiology of acne in the current era: trends and clinical implications highlighted that acne remains a highly prevalent inflammatory skin condition worldwide. This condition affects approximately 9.4% of the global population, with increasing incidence observed among both adolescents and adults, particularly women. These epidemiological trends emphasize the growing need for effective acne therapies such as topical retinoids, including adapalene, in dermatological treatment. As a result, acne consistently ranks among the most prevalent skin diseases globally, creating sustained demand for effective pharmacological treatments such as topical retinoids, including adapalene.
In addition to adolescents, adult acne is becoming increasingly common, particularly among women. Dermatological studies indicate that acne is no longer confined to teenage years, with a growing number of individuals experiencing persistent or late-onset acne beyond the age of 25. As per the article published by MDalgorithms Inc. in August 2025, it suggests that around one-fifth of adults aged 25-39 still experience acne, indicating a broader patient population requiring long-term dermatological treatment. This shift toward adult acne prevalence has significantly expanded the addressable market for topical therapies like adapalene, which is frequently used as a maintenance treatment due to its ability to prevent new lesions and control chronic inflammation.
The market is also benefiting from ongoing pharmaceutical innovation and new combination therapies incorporating adapalene. Such product developments are expanding therapeutic options and strengthening the clinical adoption of adapalene as part of multidrug acne management strategies. Furthermore, lifestyle and environmental factors are contributing to the increasing burden of acne worldwide. Rising urban pollution, dietary changes, hormonal imbalances, and stress levels have been associated with worsening acne incidence in many regions. At the same time, the growing influence of social media and increased awareness about skin health and aesthetics have encouraged more individuals to seek dermatological treatment for acne and related conditions. As acne can lead to scarring, pigmentation, and psychological distress, demand for effective treatments such as adapalene continues to rise across both prescription dermatology and over-the-counter skincare segments.
Global Adapalene Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global adapalene market report based on formulation, drug composition, prescription, indication, distribution channel, and region:
- Formulation Outlook (Revenue, USD Million, 2021 - 2033)
- Gels
- Creams
- Lotions
- Drug Composition Outlook (Revenue, USD Million, 2021 - 2033)
- Adapalene Monotherapy
- Adapalene Combination Products
- Prescription Outlook (Revenue, USD Million, 2021 - 2033)
- Over-the-Counter (OTC)
- Prescription-based
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Acne Vulgaris
- Post-Inflammatory Hyperpigmentation
- Photoaging & Skin Texture Disorders
- Follicular Keratinization Disorders
- Acne Maintenance Therapy
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
108 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Formulation
- 1.2.2. Drug Composition
- 1.2.3. Prescription
- 1.2.4. Indication
- 1.2.5. Distribution Channel
- 1.2.6. Regional scope
- 1.2.7. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Formulation Outlook
- 2.2.2. Drug Composition Outlook
- 2.2.3. Prescription Outlook
- 2.2.4. Indication Outlook
- 2.2.5. Distribution Channel Outlook
- 2.2.6. Regional Outlook
- 2.3. Competitive Insights
- Chapter 3. Adapalene Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Adapalene Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Adapalene Market: Formulation Estimates & Trend Analysis
- 4.1. Formulation Market Share, 2025 & 2033
- 4.2. Segment Dashboard
- 4.3. Global Adapalene Market by Formulation Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 4.4.1. Gels
- 4.4.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Creams
- 4.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Lotions
- 4.4.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Adapalene Market: Drug Composition Estimates & Trend Analysis
- 5.1. Drug Composition Market Share, 2025 & 2033
- 5.2. Segment Dashboard
- 5.3. Global Adapalene Market by Drug Composition Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 5.4.1. Adapalene Monotherapy
- 5.4.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.4.2. Adapalene Combination Products
- 5.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Adapalene Market: Prescription Estimates & Trend Analysis
- 6.1. Prescription Market Share, 2025 & 2033
- 6.2. Segment Dashboard
- 6.3. Global Adapalene Market by Prescription Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 6.4.1. Over-the-Counter (OTC)
- 6.4.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.2. Prescription-based
- 6.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Adapalene Market: Indication Estimates & Trend Analysis
- 7.1. Indication Market Share, 2025 & 2033
- 7.2. Segment Dashboard
- 7.3. Global Adapalene Market by Indication Outlook
- 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 7.4.1. Acne Vulgaris
- 7.4.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.2. Post-Inflammatory Hyperpigmentation
- 7.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Photoaging & Skin Texture Disorders
- 7.4.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Follicular Keratinization Disorders
- 7.4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Acne Maintenance Therapy
- 7.4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Adapalene Market: Distribution Channel Estimates & Trend Analysis
- 8.1. Distribution Channel Market Share, 2025 & 2033
- 8.2. Segment Dashboard
- 8.3. Global Adapalene Market by Distribution Channel Outlook
- 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 8.4.1. Online Pharmacies
- 8.4.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.4.2. Hospital Pharmacies
- 8.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Retail Pharmacies & Drug Stores
- 8.4.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Others
- 8.4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 9. Adapalene Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2025 & 2033
- 9.2. Regional Market Dashboard
- 9.3. Global Regional Market Snapshot
- 9.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
- 9.5. North America
- 9.5.1. U.S.
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.5.2. Canada
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.5.3. Mexico
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework/ reimbursement structure
- 9.5.3.3. Competitive scenario
- 9.5.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6. Europe
- 9.6.1. UK
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Germany
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6.3. France
- 9.6.3.1. Key country dynamics
- 9.6.3.2. Regulatory framework/ reimbursement structure
- 9.6.3.3. Competitive scenario
- 9.6.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6.4. Italy
- 9.6.4.1. Key country dynamics
- 9.6.4.2. Regulatory framework/ reimbursement structure
- 9.6.4.3. Competitive scenario
- 9.6.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6.5. Spain
- 9.6.5.1. Key country dynamics
- 9.6.5.2. Regulatory framework/ reimbursement structure
- 9.6.5.3. Competitive scenario
- 9.6.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6.6. Denmark
- 9.6.6.1. Key country dynamics
- 9.6.6.2. Regulatory framework/ reimbursement structure
- 9.6.6.3. Competitive scenario
- 9.6.6.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6.7. Sweden
- 9.6.7.1. Key country dynamics
- 9.6.7.2. Regulatory framework/ reimbursement structure
- 9.6.7.3. Competitive scenario
- 9.6.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.6.8. Norway
- 9.6.8.1. Key country dynamics
- 9.6.8.2. Regulatory framework/ reimbursement structure
- 9.6.8.3. Competitive scenario
- 9.6.8.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.7. Asia Pacific
- 9.7.1. Japan
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.7.2. China
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.7.3. India
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.7.4. Australia
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.7.5. South Korea
- 9.7.5.1. Key country dynamics
- 9.7.5.2. Regulatory framework/ reimbursement structure
- 9.7.5.3. Competitive scenario
- 9.7.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.7.6. Thailand
- 9.7.6.1. Key country dynamics
- 9.7.6.2. Regulatory framework/ reimbursement structure
- 9.7.6.3. Competitive scenario
- 9.7.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.8. Latin America
- 9.8.1. Brazil
- 9.8.1.1. Key country dynamics
- 9.8.1.2. Regulatory framework/ reimbursement structure
- 9.8.1.3. Competitive scenario
- 9.8.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.8.2. Argentina
- 9.8.2.1. Key country dynamics
- 9.8.2.2. Regulatory framework/ reimbursement structure
- 9.8.2.3. Competitive scenario
- 9.8.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.9. MEA
- 9.9.1. South Africa
- 9.9.1.1. Key country dynamics
- 9.9.1.2. Regulatory framework/ reimbursement structure
- 9.9.1.3. Competitive scenario
- 9.9.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.9.2. Saudi Arabia
- 9.9.2.1. Key country dynamics
- 9.9.2.2. Regulatory framework/ reimbursement structure
- 9.9.2.3. Competitive scenario
- 9.9.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.9.3. UAE
- 9.9.3.1. Key country dynamics
- 9.9.3.2. Regulatory framework/ reimbursement structure
- 9.9.3.3. Competitive scenario
- 9.9.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.9.4. Kuwait
- 9.9.4.1. Key country dynamics
- 9.9.4.2. Regulatory framework/ reimbursement structure
- 9.9.4.3. Competitive scenario
- 9.9.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis, By Key Market Participants
- 10.2. Company/Competition Categorization
- 10.3. Vendor Landscape
- 10.3.1. List of key distributors and channel partners
- 10.3.2. Key customers
- 10.3.3. Key company market share analysis, 2025
- 10.3.4. Galderma S.A.
- 10.3.4.1. Company overview
- 10.3.4.2. Financial performance
- 10.3.4.3. Product benchmarking
- 10.3.4.4. Strategic initiatives
- 10.3.5. Glenmark Pharmaceuticals
- 10.3.5.1. Company overview
- 10.3.5.2. Financial performance
- 10.3.5.3. Product benchmarking
- 10.3.5.4. Strategic initiatives
- 10.3.6. Teva Pharmaceuticals
- 10.3.6.1. Company overview
- 10.3.6.2. Financial performance
- 10.3.6.3. Product benchmarking
- 10.3.6.4. Strategic initiatives
- 10.3.7. Sandoz Group AG
- 10.3.7.1. Company overview
- 10.3.7.2. Financial performance
- 10.3.7.3. Product benchmarking
- 10.3.7.4. Strategic initiatives
- 10.3.8. Sun Pharmaceuticals Industries
- 10.3.8.1. Company overview
- 10.3.8.2. Financial performance
- 10.3.8.3. Product benchmarking
- 10.3.8.4. Strategic initiatives
- 10.3.9. Dr. Reddy's Laboratories
- 10.3.9.1. Company overview
- 10.3.9.2. Financial performance
- 10.3.9.3. Product benchmarking
- 10.3.9.4. Strategic initiatives
- 10.3.10. Cipla Limited
- 10.3.10.1. Company overview
- 10.3.10.2. Financial performance
- 10.3.10.3. Product benchmarking
- 10.3.10.4. Strategic initiatives
- 10.3.11. Lupin Limited
- 10.3.11.1. Company overview
- 10.3.11.2. Financial performance
- 10.3.11.3. Product benchmarking
- 10.3.11.4. Strategic initiatives
- 10.3.12. Torrent Pharmaceuticals
- 10.3.12.1. Company overview
- 10.3.12.2. Financial performance
- 10.3.12.3. Product benchmarking
- 10.3.12.4. Strategic initiatives
- 10.3.13. Zydus Lifesciences Limited
- 10.3.13.1. Company overview
- 10.3.13.2. Financial performance
- 10.3.13.3. Product benchmarking
- 10.3.13.4. Strategic initiatives
- 10.3.14. La Roche-Posay
- 10.3.14.1. Company overview
- 10.3.14.2. Financial performance
- 10.3.14.3. Product benchmarking
- 10.3.14.4. Strategic initiatives
- 10.3.15. Niksan Pharmaceutical
- 10.3.15.1. Company overview
- 10.3.15.2. Financial performance
- 10.3.15.3. Product benchmarking
- 10.3.15.4. Strategic initiatives
- 10.3.16. SoliPharma
- 10.3.16.1. Company overview
- 10.3.16.2. Financial performance
- 10.3.16.3. Product benchmarking
- 10.3.16.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
